Biopharma Company GSK to Settle 80,000 Zantac Cases for $2.2 Billion

The cases were filed after the FDA asked for market withdrawal of these drugs, citing the presence of a cancer-causing chemical.
Biopharma Company GSK to Settle 80,000 Zantac Cases for $2.2 Billion
Zantac packages and pills in a photo illustration. Drew Angerer/Getty Images
|Updated:
0:00

Biopharma company GSK reached settlement agreements with 10 law firms representing multiple plaintiffs in cases related to the company allegedly selling carcinogenic drugs.

The settlement affects about 80,000 cases managed by these law firms, which represent 93 percent of lawsuits filed in the United States against GSK for its Zantac drug, according to an Oct. 9 company statement. “Under these agreements, GSK will make an aggregate payment of up to $2.2 billion to resolve all U.S. state court product liability cases,” it reads.
Naveen Athrappully
Naveen Athrappully
Author
Naveen Athrappully is a news reporter covering business and world events at The Epoch Times.